Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale

Fernando Bianchini Cardoso*, Lígia M. Antunes-Correa*, Thiago Quinaglia A. C. Silva*, Luis Miguel Silva, Camilla Toledo, Vinicius Citelli Ribeiro, Layde R. Paim, Tomas G. Neilan, Lício Velloso, Wilson Nadruz, Celso Dario Ramos, Sergio S. Dertkigil, Roberto Schreiber, Andrei Sposito, Jose Roberto Matos-Souza, Otávio Berwanger, Michael Jerosch-Herold and Otávio Rizzi Coelho-Filho

Abstract
Background: Studies have shown significant benefits of exercise therapy in heart failure (HF) with a reduced ejection fraction (HFrEF) and HF with a preserved ejection fraction (HFpEF). The mechanisms responsible for the beneficial effect of exercise in HFrEF and HFpEF are still unclear. We hypothesized that the effect of exercise on myocardial remodeling may explain its beneficial effect.

Methods: IMAGING-REHAB-HF is a single-center, randomized, controlled clinical trial using cardiac magnetic resonance imaging, vasomotor endothelial function, cardiac sympathetic activity imaging and serum biomarkers to compare the effect of exercise therapy in HFpEF (LVEF ≥ 45%) and HFrEF (LVEF < 45%). Subjects will be assessed at baseline and after 4 months. The exercise program will consist of three 60-min exercise sessions/week. The primary endpoints are the effect of exercise on myocardial extracellular volume (ECV), left ventricular (LV) systolic function, LV mass, LV mass-to-volume and LV cardiomyocyte volume. Secondary endpoints include the effect of exercise on vasomotor endothelial function, cardiac sympathetic activity and plasmatic biomarkers. Patients will be allocated in a 2:1 fashion to supervised exercise program or usual care. A total sample size of 90 patients, divided into two groups according to LVEF: HFpEF group (45 patients:30 in the intervention arm and 15 in the control arm) and HFrEF group (45 patients:30 in the intervention arm and 15 in the control arm) – will be necessary to achieve adequate power.

Conclusion: This will be the first study to evaluate the benefits of a rehabilitation program on cardiac remodeling in HF patients. The unique design of our study may provide unique data to further elucidate the mechanisms involved in reverse cardiac remodeling after exercise in HFpEF and HFrEF patients.

Keywords: biomarkers, exercise-training, fibrosis, left ventricular remodeling, magnetic resonance imaging, rehabilitation program, T1 mapping techniques

Received: 19 March 2019; revised manuscript accepted: 12 July 2019.
**Introduction**

Heart failure (HF) is a clinical syndrome associated with substantial healthcare costs, high hospitalization rates and premature mortality.\(^1\) Primarily due to the global rise in aging, obesity and other risk factors, the incidence and prevalence of HF will increase.\(^{1,2}\) More recently, the syndrome has been categorized into three groups, according to the left ventricular (LV) ejection fraction (LVEF): HF with reduced LVEF or LVEF \(\leq 40\%\) (HFrEF); HF with preserved LVEF or LVEF \(\geq 50\%\) (HFpEF); and HF with mid-range LVEF of 40–49\% (HFmrEF).\(^3\) However, during the last decades, HFrEF was historically characterized by LVEF \(< 45\%\), and HFpEF by LVEF \(\geq 45\%\). In the present study, we will use 45\% LVEF as a threshold to divide the HF groups.

Numerous studies have shown a similar and markedly elevated risk of mortality between HFpEF and HFrEF.\(^4,5\) For example, Lee and colleagues showed similar long-term prognoses between HFpEF and HFrEF patients, adjusted for age and sex. The mortality was equally high in both groups (74\% and 95\% at 5 and 10 years, respectively).\(^6\) In recent years, pharmacological treatment of HFrEF has significantly improved through control of neurohormonal cascade, including adrenergic and renin–angiotensin–aldosterone system blockade.\(^7\) In contrast, many pharmacological treatment trials showed neutral or negative results in the prognosis of HFpEF patients.\(^7-12\)

The HFpEF phenotype is characterized by concentric/restrictive LV remodeling, and HFrEF is commonly characterized by eccentric/dilated LV remodeling, whereas both phenotypes contribute to cardiac dysfunction and the progression of HF.\(^13,14\) Different patterns of extracellular cardiac fibrosis\(^15\) and cardiomyocyte adaptations\(^16\) may help to explain the different phenotypes, and why responses to treatment might be different between these two conditions. Despite heterogeneity regarding therapeutic responses, nonpharmacological approaches may potentially affect outcomes across the full spectrum of HF. Exercise training programs improve functional capacity and quality of life,\(^17-19\) improve endothelial and muscular functions\(^20,21\) and may reduce neurohormonal activation in HFrEF.\(^17-19\) The benefits of exercise training in HFpEF patients are less studied, but the available evidence suggests that exercise could also improve functional limitations and quality of life.\(^22,23\) Some observations also showed that rehabilitation programs may improve cardiac function and reduced hospitalization in patients with both HFrEF and HFpEF (Table 1).\(^24-26\) However, the potential effects of an exercise rehabilitation program on cardiac remodeling, a surrogate marker for clinical outcomes, remains poorly investigated in HFrEF and HFpEF patients.\(^27,28\)

Our group has recently developed novel magnetic resonance imaging (MRI) markers of myocardial remodeling that may be useful in this scenario. Based on the MRI T1-mapping imaging, both the expansion of extracellular volume (ECV), a marker of interstitial fibrosis, and the intracellular lifetime of water \((\tau_{ic})\), a marker of cardiomyocyte size and cellular hypertrophy,\(^32\) can be accurately characterized. ECV is a strong independent predictor of adverse cardiovascular events and has excellent potential prognostic value.\(^33-35\) In addition, we have validated this technique histologically in a mouse model of pressure overload, demonstrating that: (1) the MRI biomarker may capture the dynamic tissue physiology and treatment effects in HF models;\(^36\) and (2) it differentiates cellular hypertrophy from interstitial fibrosis serially during the development of both phenotypes after pressure overload.\(^32\) In the present study, we hypothesize that exercise training may have a favorable effect on myocardial tissue remodeling in HF patients. We further hypothesize that the effect of exercise on myocardial remodeling, systolic and diastolic function, cardiac sympathetic activity and plasmatic biomarkers may be different between HFrEF and HFpEF patients. In addition, we expect that exercise training may have a favorable effect attenuating cardiomyocyte hypertrophy and interstitial fibrosis, decreasing cell size and myocardial interstitial fibrosis. Changes are also expected in circulating microRNAs and in sympathetic cardiac activity. These novel and investigative changes may be able to differentiate the role of rehabilitation in myocardial remodeling of patients with HFpEF and HFrEF.

**Methods**

**Study design**

IMAGING-REHAB-HF is a single-center (UNICAMP, Campinas, SP, Brazil), randomized, open-label, placebo-controlled clinical trial to compare the effect of a standardized HF rehabilitation protocol with usual care, including guideline-driven optimized medical therapy for HF, on.

---

**Note:** The text is cut off at the end, indicating it continues beyond the visible portion.
Table 1. The effects of exercise training on systolic and diastolic function in HfPEF.

| Study       | Group (n) | Age (years) | Men (%) | LVEF (% mean) | BNP (pg/ml) (mean) | Training program                                                                 | Duration protocol | Main endpoints | Results                                                                 |
|-------------|-----------|-------------|---------|---------------|-------------------|----------------------------------------------------------------------------------|-------------------|----------------|-------------------------------------------------------------------------|
| Kitzman et al.29 | n = 63    | 70 ± 7      | 24      | 58 ± 6        | 64.8 ± 74.5       | Aerobic supervised exercise (track walking + cycling) three times per week, with gradually increasing duration and intensity. | 16 weeks          | 1. Peak VO2. 2. Brachial artery FMD (flow-mediated arterial dilation) in response to cuff ischemia 3. Carotid artery distensibility 4. LV function 5. Quality of life (QoL) | Peak VO2 ↑ QoL ↑ Brachial artery FMD and carotid arterial ↔ Resting LV systolic and diastolic function ↔ |
|             | 32 EG     |             |         |               |                   | Intensity: 40–50% of peak VO2 to 60–70%. Duration increased to 15–20 min. |                   |                |                                                                           |
|             | 31 CG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
| Edelmann et al.30 | n = 64   | 65 ± 7      | 64      | 67 ± 7        |                   | Supervised, endurance (cycling) + resistance training Aerobic training. Week 1–4: at 50–60% of baseline peak VO2 and week 5–12: 70% + resistance training | 24 weeks          | 1. Peak oxygen uptake. 2. Systolic, diastolic function by echo 3. LV dimensions 4. QoL | Exercise capacity ↑ QoL ↑ Atrial reverse remodeling ↑ Left ventricular diastolic function ↑ |
|             | 44 EG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
|             | 20 CG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
| Smart et al.31 | n = 25    | 64.4 ± 6.4  | 52      | 58.9 ± 11.9   | 12.2 ± 3.6        | Supervised, outpatient cycle ergometer exercise training. Initial intensity of 60–70% peak VO2, up-titrated by 2 to 5 watts/week as tolerated. | 16 weeks          | 1. Peak oxygen uptake. 2. Systolic, diastolic function by echo 3. LV dimensions 4. QoL | Peak VO2 in the exercise ↑ V̇̇O2/ĊO2 slope ↓ Diastolic or systolic function ↔ QoL and depression scores ↔ |
|             | 12 EG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
|             | 13 CG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
| Alves et al.32 | n = 31    | 62.9 ± 10.2 | 71      | 56.3 ± 2.5    | 13.65 ± 4.9       | Supervised endurance training (treadmill/ cycle. Week 1–4: training at 70–75% of peak VO2 and week 5–24: training at 70–75% of peak VO2. | 24 weeks          | 1. Peak oxygen uptake. 2. Systolic, diastolic function by echo 3. LV dimensions 4. QoL | Exercise tolerance ↑ LVEF ↑ Diastolic function ↑ Left ventricular dimensions ↔ |
|             | 20 EG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
|             | 11 CG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
| Fu et al.33  | n = 60    | 60.5 ± 2.7  | 66      | 57.6 ± 1.9    |                   | 30 min of cycling, three times/week 80% of peak VO2 | 12 weeks          | 1. Peak oxygen 2. Systolic, diastolic function by echocardiogram 3. QoL | LVEF ↔ Diastolic function ↑ VO2 peak ↑ V̇̇O2/ĊO2 slope ↓ QoL ↑ |
|             | 30 EG     |             |         |               |                   |                                                                    |                   |                |                                                                           |
|             | 30 CG     |             |         |               |                   |                                                                    |                   |                |                                                                           |

BNP, brain natriuretic peptide; EG, exercise group; CG, control group; LVEF, left ventricular ejection fraction; peak VO2, oxygen uptake during peak exercise; V̇̇O2/ĊO2, ventilator efficiency; ↑, increase and/or improvement; ↓, decrease and/or worsen; ↔, maintenance/neutral effect.
myocardial tissue remodeling across four groups of HF patients: HFrEF (rehabilitation or usual care) and HFPpEF (rehabilitation or usual care). During the screening process, therapy for HF will be carefully reviewed to identify individuals under maximal medical therapy, including, when clinically indicated by recent guidelines, the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, beta blockers, mineralocorticoid receptor antagonists and more recently angiotensin receptor–neprilysin inhibitor.

Our research team will contact all cardiologists from our hospital network to refer HF patients. In addition to that, we will also contact and advertise the current protocol in other neighborhood health institutions. All recruited patients, in both HFPpEF and HFrEF groups, will maintain optimal HF medical therapy after randomization according to the most recent guidelines.37,38 Patients with HFrEF and HFPpEF will be enrolled as indicated in the study design flow chart (Figure 1). Quickly after recruitment, HFPpEF and HFrEF patients will be randomly allocated to rehabilitation or usual care in a 2:1 fashion, in blocks of 6 patients, to achieve a total of 30 individuals for each intervention arm and 15 in each control arm (randomization will be performed using the website https://www.sealedenvelope.com), giving a total of 90 patients: 45 HFPpEF and 45 HFrEF patients. Regardless of allocation group, patients will be motivated to follow all clinical recommendations and to follow protocol steps. Our research staff will contact patients to remind them about their research appointments and visits. All participants will receive a unique random code as ID and all protected health information (PHI) will be protected using HIPAA-compatible encryption. All collected variables will be entered blinded to any PHI. Data will be stored in a .csv format using a home-developed database stored on a safe local network. Our team will search for duplicate entries and entries with abnormal value ranges every week in a fashion blinded to any patient-sensitive information. Data source files will be available for independent quality control assurance. Variables of interest will be obtained at baseline (before intervention initiation) and after 4 months of supervised rehabilitation or usual care.

The UNICAMP Research Ethics Committee under the registration number CAAE: 53967215.8.0000.5404 approved the study (ClinicalTrials.gov identifier: NCT03084679). All patients will provide written informed consent prior to participation in the study. Detailed research procedures, including all clinical visits as well as all blood tests and quality of life (QoL) questionnaires, are displayed in Table 2. Inclusion and exclusion criteria are displayed below. Additional design details according to the most recent SPIRIT recommendation for interventional trials are available (online supplemental file in the online-only data supplement).

Inclusion criteria for HFrEF:

- Age 18–75 years.
- Functional limitation (New York Heart Association class II or worse).
- Evidence of LVEF dysfunction (LVEF < 45% assessed by transthoracic echocardiogram using Simpson's method) within 3 months of recruitment.
- No contraindications to exercise (by ACC/AHA criteria39).
- Cardiac MRI eligible criteria (no metallic hazards, eGFR > 40 ml/min/1.73 m², etc.).
- A prior diagnosis of HF (by Framingham criteria).
- Stable diuretic therapy and euvolemic status (as assessed by an attending cardiologist within 1 month of cardiopulmonary exercise testing).
- Qualifying echocardiography.

Inclusion criteria for HFPpEF:

- Age 18–75 years.
- Functional limitation (New York Heart Association class II or worse).
- Evidence of LVEF dysfunction (LVEF ≥ 45% assessed by transthoracic echocardiogram using Simpson's method) within 3 months of recruitment.
- No contraindications to exercise (by ACC/AHA criteria39).
- Cardiac MRI eligible criteria (no metallic hazards, eGFR > 40 ml/min/1.73 m², etc.).
- A prior diagnosis of HF (by Framingham criteria).
- Stable diuretic therapy and euvolemic status (as assessed by an attending cardiologist within 1 month of cardiopulmonary exercise testing).
- Qualifying echocardiography.
Figure 1. (a) Study flow chart for heart failure with reduced ejection fraction (HFrEF). (b) Study flow chart for heart failure with preserved ejection fraction (HFpEF). CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise testing; ECHO, echocardiographic evaluation; LVEF, left ventricular ejection fraction; HF, heart failure; MIBG, $^{[131]}$I/$^{[123]}$I metaiodobenzylguanidine.
## Table 2. Overview of all visits and tests scheduled for participants of the IMAGING-REHAB-HF trial.

| Procedures                                                                 | Screening | Visit 1 baseline/randomization | Rehabilitation visits 3 × week for 4 months (only for patients allocated to rehabilitation) | Tele call every 4 weeks ± 3 d | Usual clinical visits every 7 d every 2 months ± 7 d | Final visit |
|---------------------------------------------------------------------------|-----------|--------------------------------|---------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------|------------|
| Informed consent                                                          | X         |                                |                                                                                             |                             |                                                     |            |
| Check inclusion/exclusion criteria                                        | X         |                                |                                                                                             |                             |                                                     |            |
| Medical history and family history                                        | X         |                                |                                                                                             |                             |                                                     |            |
| Clinical examination                                                      | X         | X                              |                                                                                             | X                           |                                                     |            |
| Demographics                                                              | X         |                                |                                                                                             |                             |                                                     |            |
| Vital signs                                                               | X         | X                              | X                                                                                           | X                           | X                                                   |            |
| Safety blood tests and NT-Pro-BNP                                         | X         | X                              |                                                                                             | X                           | X                                                   |            |
| Research blood                                                            | X         |                                |                                                                                             | X                           |                                                     |            |
| Genetic blood sample                                                      | X         |                                |                                                                                             | X                           |                                                     |            |
| MRI                                                                       | X*        |                                |                                                                                             |                             |                                                     |            |
| MIBG                                                                      | X*        |                                |                                                                                             |                             |                                                     |            |
| ECHO                                                                       | X         |                                |                                                                                             | X                           |                                                     |            |
| FMD                                                                        | X         |                                |                                                                                             | X                           |                                                     |            |
| CPET                                                                       | X+        |                                |                                                                                             |                             |                                                     |            |
| QoL questionnaires                                                        | X         |                                |                                                                                             |                             |                                                     |            |
| Supervised rehabilitation                                                 | X         | X                              |                                                                                             |                             |                                                     |            |
| Adverse event assessment                                                  | X         | X                              | X                                                                                           | X                           | X                                                   |            |
| Record or review concomitant meds                                         | X         | X                              | X                                                                                           | X                           | X                                                   |            |
| Check adherence to optimal HF therapy                                     | X         | X                              | X                                                                                           | X                           | X                                                   |            |

*a*Screening MRI to be done only if echo criteria fulfilled. Note MRI can be done up to 12 weeks before visit 1.

*b*Screening mIBG to be done only if echo criteria fulfilled. Note mIBG can be done up to 12 weeks before visit 1.

*c*Screening CPET to be done only if echo criteria fulfilled. Note MRI can be done up to 12 weeks before visit 1.

*d*Final MRI can be done up to 4 weeks after the final visit.

*e*Final mIBG can be done up to 4 weeks after the final visit.

*f*Final CPET can be done up to 4 weeks after the final visit.

CPET, cardiopulmonary exercise testing; ECHO, echocardiographic evaluation; FMD, flow-mediated arterial dilation; MIBG, [131I]/[123I] metaiodobenzylguanidine; MRI, magnetic resonance imaging; NT-Pro-BNP, N-terminal pro b-type natriuretic peptide; QoL, quality of life.
Exclusion criteria:

- Severe ischemia by stress testing in the prior 6 months of screening.
- Hypertrophy cardiomyopathy or infiltrative heart disease (e.g. amyloidosis).
- Severe COPD (FEV₁ < 1 L), severe pulmonary hypertension (PA systolic pressure > 60 mmHg) not due to left HF.
- Severe right- or left-sided valvular heart disease (stenosis or regurgitation).
- Myocardial infarction (by serum troponin > 99th percentile with clinical syndrome) or revascularization within 3 months of screening.
- Anemia (hemoglobin < 10 g/dl) within 1 month of CPET (cardiopulmonary exercise testing).
- Severe hepatic disease.
- Systolic BP < 95 mmHg at the screening visit.
- Unable to walk or to perform cardiopulmonary exercise testing.
- Malignancy (receiving active treatment) or other life-threatening diseases.
- Pregnant or lactating women.
- Participation in any other clinical trial within the previous 30 days.
- Atrial fibrillation.

Cardiac MRI
Cardiac MRI studies will be performed at 3 tesla (Achieva, Philips Medical Systems, Best, the Netherlands) with a six-element phased-array coil. The cardiac MRI protocol will include the following EKG gated sequences: precontrast T1 measurement; myocardial cine tagging with radial read-outs at 5° flip-angle excitations; cine myocardial function assessment with retrospectively gated SSFP technique (TR/TE/flip-angle = 5/2.2 ms/10°; slice thickness = 8 mm; 192 × 100 matrix; FOV = 340 × 30–340 mm; NEX = 1 and a SENSE of 2 for parallel imaging acceleration), as used previously in studies by our group. T1 measurements will be made at three slice locations (basal, mid, apical), with one slice imaged per 15–20 s breath-hold. We will acquire five T1 datasets in each patient. A two-site model of 1H exchange will be used to fit both τₑ and ECV.

Cardiac sympathetic imaging with ¹²³I-mIBG
To assess sympathetic hyperactivity in the heart, planar and SPECT/CT (single photon emission computed tomography/computed tomography) images of the myocardial innervation will be performed after the intravenous administration of 111–185 MBq (3–5 mCi) of ¹²³I-mIBG (IPEN, Rio de Janeiro, Brazil). The images will be obtained 15–30 min (early) and 3–4 h (delayed) after radiopharmaceutical injection using SPECT/CT equipment (Symbia T2, Siemens Healthcare, Erlangen, Germany). A heart-to-mediastinum uptake ratio (H/M) will be obtained by drawing regions of interest (ROIs) over the heart and mediastinum. SPECT/CT images of the heart will be used to evaluate the regional sympathetic activity. ¹²³I-mIBG SPECT images will also be compared with stress and rest ⁹⁹ᵐTc-sestamibi-SPECT myocardial perfusion images performed on a separate day within 1 week to account for differences between regional innervation and perfusion. Cardiac sympathetic hyperactivity is associated with HF progression, arrhythmias and cardiac death. ¹²³I-mIBG uptake and its distribution in the myocardium will be evaluated by a trained and certified nuclear physician using a semi-quantification method (H/M ratio) and polar maps obtained from the SPECT images. Early and late cardiac uptake of ¹²³I-mIBG will be used to calculate the cardiac washout rate of ¹²³I-mIBG.

Cardiopulmonary exercise testing
CPET will be performed using established standard clinical methods. CPET provides several physiologic measurements indicative of acute cardiovascular adaptation to exercise and

journals.sagepub.com/home/taj
cardiovascular reserve capacity. Measurement of these quantitative parameters will permit the determination of fundamental relationships between myocardial tissue and cardiovascular reserve capacity. Patients will undergo maximum ramp protocol with work rate increment of 5–15 watt/min every minute until exhaustion on cycle ergometry (MedGraphics, St. Paul, USA) as described earlier. The respiratory gas exchange will be measured at rest and during exercise (Medical Graphics Corp, St. Paul, USA). Oxygen uptake (VO₂), carbon dioxide output (VCO₂), and respiratory exchange ratio will be calculated by the gas exchange on a breath-by-breath basis in a computerized system. Peak VO₂ will be defined as the highest O₂ uptake, averaged over 30 s, during the last minute of symptom-limited exercise. We will also assess, as previously described: (1) anaerobic threshold (AT) and respiratory compensation point (RCP); (2) oxygen pulse; (3) ventilatory efficiency (V̇E/V̇CO₂ slope); (4) exercise oscillatory ventilation (EOV); (5) oxygen uptake efficiency slope (OUES); and (6) aerobic efficiency (VO₂/watt).

Echocardiographic data analysis
Two-dimensional echocardiographic evaluation (Vivid-S60, GE-Healthcare, Milwaukee, USA) will be undertaken with patients in a left lateral decubitus with a 3.5 MHz transducer in a standardized manner as approved by current American Society of Echocardiography (ASE) guidelines. LV diastolic function, including tissue Doppler myocardial velocities (acquired in early diastole at the anterior, inferior, lateral and septal mitral annulus in the apical two-chamber and four-chamber) will be assessed in all patients also following recent ASE recommendations. Peak systolic longitudinal strain and strain rate of the left ventricle contraction will be performed using speckle-tracking based imaging. All data will be stored in cine-loop format and will be analyzed blinded to patients’ information.

Flow-mediated dilation
Flow-mediated dilation enables assessment of the vasomotor function of the endothelium and correlates with cardiovascular prognosis. The procedure happens as follows. After overnight fasting and avoidance of vasoactive medications for the previous 24 h, the patient is placed lying down in a quiet room with a controlled temperature (20–22°C). A cuff is placed around the forearm and baseline measurements of the brachial artery are obtained: diameter and flow parameters. The cuff is then inflated up to 50 mmHg above the systolic blood pressure for 5 min. After 5 min of ischemia of the limb, the cuff is deflated and the baseline parameters are reassessed. Brachial artery measurements will be performed using a high-resolution ultrasound (Vivid S-60). Percentage change in brachial diameter and flow parameters will be calculated. Flow parameters are the velocity–time integral of the antegrade and retrograde brachial flow, as determined by Doppler flow evaluation, and the derived parameters of blood flow (the product of cross-sectional area and Doppler velocity) and shear rate (four times velocity divided by the arterial diameter). An independent physician will analyze videos offline a posteriori. These are validated methods used for covariate adjustment and macro- and microvascular function. The same experienced physician blinded to patients’ data will analyze brachial artery reactivity.

Biochemical and biomarkers analysis
Peripheral blood samples will be collected at baseline and after 16 weeks of the rehabilitation program or the usual care. The analysis will include: glucose (mg/dl), glycated hemoglobin (%), triglycerides (mg/dl), high- and low-density lipoprotein cholesterol (mg/dl), high-sensitivity C-reactive protein (CRP, mg/dl), creatinine kinase (CK, mg/dl), creatinine kinase muscle/brain fraction (CKMB, mg/dl), high-sensitivity troponin T (cTnT) and N-terminal pro-b-type natriuretic peptide (NT-pro-BNP) and interleukin-6 (IL-6). Hemoglobin (pg/dl), hematocrit (%), total white blood count (g/dl) and glomerular filtration rate (GFR, ml/min/1.73 m²), as well markers of collagen metabolism (synthesis and degradation), comprising C-terminal propeptide of type I procollagen (PICP, μg/L), matrix metalloproteinase 1 (MMP-1, ng/ml) and tissue inhibitor of metalloproteinase 1 (TIMP-1, ng/ml) will also be measured.

Detection and quantification of miRNAs by quantitative PCR
The expression of serum miRNAs will be performed at baseline and after the rehabilitation program in all HF groups. At baseline, the expression of serum miRNAs will be assessed using the
TaqMan OpenArray Human MicroRNA system, a quantitative polymerase chain reaction (qPCR)-based miRNA array platform that contains 754 microRNAs on a microfluidic platform across two sets of primer pools, panel A and B (Life Technologies, Carlsbad, California, USA), as previously reported.54 The serum expression of miRNAs that show different expression between the HFpEF and HFrEF groups at baseline will be reanalyzed by real-time PCR after the rehabilitation program in HF patients. Recently, a series of circulating miRNA were shown to provide adequate differentiation between HFrEF and HFpEF,55,56 enhancing the characterization of HF subtypes over traditional biochemical and imaging biomarkers. Based on this observation, we will evaluate whether any miRNA evaluated at baseline will predict changes in CPET, MRI and NT-pro-BNP analyses after the rehabilitation program.54

Rehabilitation intervention
The rehabilitation program was previously described to improve functional capacity in HFrEF patients.57 The exercise program will be conducted for 16 weeks, three 60-min exercise sessions per week (Figure 2). Each exercise session will consist of 30 min of aerobic exercise on an ergometer bicycle or on a treadmill in the first 2 weeks and up to 40 min in the rest of the period, 15 min of local strengthening exercises and 5 min of cool-down with stretching exercises. The exercise intensity will be established by heart rate levels that correspond to the AT up to 10% below the RCP obtained in the CPET. When a training effect is observed, the bicycle work rate or the velocity will be increased to return to the target heart rate levels.57 Patients will undergo exercise training under supervision at UNICAMP. The untrained patients will be instructed to avoid any regular exercise program but should retain their daily habits.

The rehabilitation exercise protocol has been shown to be not only safe but also to improve outcomes in HF patients. Although we don’t expected an increased incidence of side-effects with the current intervention, any side-effects will be collected and graded according to the most recent Common Terminology Criteria for Adverse Events (NCI CTCAE). In addition, the current intervention will be discontinued if patients demonstrate any signs of significant clinical deterioration or decompensated HF.

Study outcomes
Primary outcomes. The primary outcome of the current study is to investigate whether the rehabilitation program compared to usual care is associated with significant favorable myocardial remodeling assessed by cardiac MRI determination of ECV in noninfarcted segments (i.e. myocardium without LGE).

Secondary outcomes. The secondary outcomes will assess whether the intervention will modify established cardiac MRI of myocardial remodeling and echocardiographic myocardial strain parameters, prognostic indicators derived from CPET, biochemical laboratory parameters, including conventional and novel HF biomarkers, cardiac sympathetic activity, and peripheral endothelial function as indicated in Table 3.

Sample size and power calculations and statistical methods. The primary outcome of the present study is ECV change after intervention or usual
Therapeutic Advances in Chronic Disease 10

The sample size calculation for this study was based on a previous estimate of a clinically meaningful change of histological fibrosis (i.e. collagen volume fraction) amounting to 3%, which corresponds to an approximately 0.038 change of ECV. This estimate of the ECV change for a 3% increase of histological fibrosis was derived from the average observed correlation between histological fibrosis and ECV in various diseases such as hypertension and aortic stenosis. To detect an ECV change of this magnitude in myocardial regions without LGE (i.e. non-infarcted) with 80% power and an alpha error of 0.05 requires >27 individuals for each HF group receiving the intervention under investigation.58

Numeric data will be presented as means ± standard deviation, proportions, or medians (interquartile range) according to its distribution. t tests, for continuous data, and Fisher’s test or χ² test, for dichotomous data, will be used to compare baseline variables. Changes after rehabilitation (usual care versus rehabilitation) among groups (HFpEF and HFrEF) will be assessed by analysis of covariance and/or liner mixed effect (LME) regression models (package lme4 in R) when appropriate. Post-hoc comparisons adjusted for multiple testing will be applied for secondary analyses. Pearson’s method or Spearman rank correlation will be used to assess statistical dependence between variables. Analyses will be performed with SAS 9.4 (SAS Institute, Inc., Cary, USA) and using R (version 3.3.2, R Foundation; http://www.R-project.org).

Discussion

The present proposed study is a prospective and randomized trial, designed to determine whether the rehabilitation program causes different effects on the reverse remodeling of myocardial tissue and on the cardiac function in patients with HFpEF and HFrEF, respectively. This is the first study that evaluates the benefits of moderate aerobic exercise training on interstitial fibrosis, cardiomyocyte size and cellular hypertrophy in patients with HF. In addition, this trial will provide novel evidence to investigate the effects of exercise training on reverse myocardial tissue remodeling. The design of our study may provide

| Primary and secondary outcomes. | MRI | ECHO | CPET | MIBG | Biomarkers | FMD |
|-------------------------------|-----|------|------|------|------------|-----|
| LVEDVi (ml/m²)               | GLS | Peak VO₂ AT | Early [¹²³I] mIBG H/M | NT-proBNP, IL-6, cTnT, PICP, MMP-1 TIMP-1. | Brachial dilatation |
| LVESVi (ml/m²)               | GCS | RCP  | Late [¹²³I] mIBG H/M | Hb (pg/dl), Ht (%), WBC [10⁹/mm³] | Blood flow |
| LVMi (g/m²)                  | Strain Rate | EOV | HDL (mg/dl), LDL (mg/dl, Trig (mg/dl) | Shear rate |
| LAVi (ml/m²)                 | Strain Rate | EOV | Hb (pg/dl), Ht (%), WBC [10⁹/mm³] | Blood flow |
| Intracellular lifetime of water [τic] extracellular volume fraction | Oxygen pulse VO₂/watt | Glucose (mg/dl), glycated hemoglobin [%] | |
|                              |                               |                               | GFR, CK (mg/dl), CKMB (mg/dl) | |

AT, anaerobic threshold; CK, creatinine kinase; CKMB, creatinine kinase muscle/brain fraction; CRP, high-sensitivity C-reactive protein levels; cTnT, high-sensitivity troponin T; EOV, exercise oscillatory ventilation; GCS, global circumferential strain; GFR, glomerular filtration rate; GLS, global longitudinal strain; Hb, hemoglobin; HDL, high-density lipoprotein; H/M, heart-to-mediastinum ratio; Ht, hematocrit; IL-6, interleukin 6; LAV, left atrium volume [LAV]; LDL, low-density lipoprotein; LVEDVi, left ventricle end diastolic volume; LVMi, left ventricle mass index; LVESVi, left ventricle end systolic volume; MMP-1, matrix metalloproteinase 1; NT-pro-BNP, N-terminal pro b-type natriuretic peptide; OUES, oxygen uptake efficiency slope; PICP, C-terminal propeptide of type I procollagen; RCP, respiratory compensation point; V̇ₐ/ₐCO₂, ventilatory efficiency; VO₂/watt, aerobic efficiency; TIMP-1, tissue inhibitor of metalloproteinase 1; Trig, triglycerides; WBC, white blood cells.
unique data to further elucidate the mechanisms involved in reverse myocardial tissue remodeling, by comparing it with changes in cardiac sympathetic activity, plasmatic biomarkers, and miRNA after the rehabilitation program in HF patients.

Exercise training is an important, effective and safe strategy, class I recommendation, for treatment of patients with stable class II to III HF. The rehabilitation program is associated with important reductions in adverse events and hospitalization of patients with HFrEF or HFrEF. Moreover, poor and intermediate physical activity levels were associated with a twofold increased risk of HF hospitalization and mortality in patients with HFrEF.

Despite the consolidated positive systemic effects of regular exercise training in HF patients, the benefits of exercise training on myocardial tissue remodeling and cardiac function remain controversial. Evidence suggests that exercise training could improve functional and structural changes in the LV. In HF animal models, exercise training increases fractional shortening and reduces cross-sectional fiber diameter and cardiac collagen volume. Several reports have investigated the effects of different cardiac rehabilitation programs on myocardial remodeling in CAD patients with HF with preserved and reduced EF. In patients with HFrEF, some studies showed that exercise training could improve cardiac output, stroke volume, and LVEF, while other studies did not show benefits of exercise training on cardiac function. Erbs and colleagues showed that moderate aerobic exercise training has a beneficial effect on stroke volume, cardiac output and LVEF in advanced chronic HFrEF patients. Exercise training also significantly improves the ratio E/E', suggesting an improvement in diastolic function in patients with either HFrEF or HFrEF. Although the beneficial effects of exercise training have been seen in some of these observations, partially improving various markers of LV remodeling, none of these studies specifically assessed myocardial tissue phenotyping using recently developed noninvasive imaging modalities.

The potential for reverse remodeling of myocardial tissue could be associated with the level of cardiomyocyte hypertrophy and interstitial collagen content. Unfortunately, standard, clinically available imaging methods are limited in evaluating myocardial tissue properties. The current imaging methods detect large and advanced tissue pathologies in patients, like necrosis by late gadolinium enhancement with cardiac MRI, but cannot detect small and earlier tissue changes. Novel cardiac MRI techniques to quantify the cardiomyocyte hypertrophy and interstitial expansion are noninvasive and applicable in patients. Using these innovative cardiac MRI techniques, the present study will show the effects of a regular program of exercise on interstitial fibrosis, cardiomyocyte diameter and cellular hypertrophy in patients with HF. It is well known that pharmacological treatment has different effects on reverse remodeling in HFrEF and HFrEF, so it is possible that exercise training also has different effects on myocardial tissue in patients with HFrEF and HFrEF. The present study is the first to compare the effects of exercise training on cardiac function and phenotype in both HFrEF and HFrEF. In addition, we explore whether cardiac sympathetic activity, endothelial dysfunction and/or miRNAs explain the differences between responses to intervention regarding reverse remodeling and improvement in plasmatic biomarkers.

Conclusion
HF is a burdensome condition associated with high healthcare costs. Although major clinical trials have shown benefits of pharmacological treatment, particularly in HFrEF, morbidity and mortality do not differ significantly between the two spectra of the disease (HFrEF and HFrEF). In parallel, evidence suggests exercise training programs may be beneficial for both HFrEF and HFrEF patients, but little is known about their effect on cardiac remodeling. In this study, we aim to evaluate the possible effects of moderate aerobic exercise training on interstitial fibrosis, cardiomyocyte size and cellular hypertrophy in HF patients. The unique design of our study may provide data to further elucidate the mechanisms involved in the reverse myocardial tissue remodeling, by assessment of cardiac sympathetic activity, plasmatic biomarkers and miRNA changes after the rehabilitation.

Funding
The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: Dr. Coelho-Filho is supported by the National Council for Scientific and Technological Development (CNPq) Productivity in Research award grant (303366/2015-0) and
travel award grant (453960/2016-2). Dr. Coelho-Filho is also supported by a Young Investigators Grant from the São Paulo Research Foundation (2015/15402-2). Dr. T. Neilan was supported in part through a kind gift from C. Kurt Greer and Pamela Kohlberg, National Institutes of Health/National Heart, Lung, and Blood Institute (1R01HL130539-01A1; 1R01HL137562-01A1; K24HL113128-06) and National Institutes of Health/Harvard Center for AIDS Research (P30AI060354).

Conflicts of interest statement
The author(s) declared following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Neilan reports consultancy for Parexel, Intrinsic Imaging, BMS and Aprea Therapeutics unrelated to the contents of this article. The other authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

ORCID iD
Otávio Rizzi Coelho-Filho https://orcid.org/0000-0003-4428-5186

References
1. McMurray JJ and Pfeffer MA. Heart failure. Lancet 2005; 365: 1877–1889.
2. Dunlay SM, Roger VL and Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017; 14: 591–602.
3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European society of cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975.
4. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209–2216.
5. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750–1757.
6. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119: 3070–3077.
7. Shah SJ. Innovative clinical trial designs for precision medicine in heart failure with preserved ejection fraction. J Cardiovasc Transl Res 2017; 10: 322–336.
8. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345.
9. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003; 362: 777–781.
10. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456–2467.
11. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383–1392.
12. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268–1277.
13. González A, Schelbert EB, Díez J, et al. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol 2018; 71: 1696–1706.
14. Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 2015; 89: 1401–1438.
15. Kong P, Christia P and Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014; 71: 549–574.
16. Piek A, de Boer RA and Siljé HH. The fibrosis–cell death axis in heart failure. Heart Fail Rev 2016; 21: 199–211.
17. Fraga R, Franco FG, Roveda F, et al. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. Eur J Heart Fail 2007; 9: 630–636.
18. de Mello Franco FG, Santos AC, Rondon MU, et al. Effects of home-based exercise training on neurovascular control in patients with heart failure. *Eur J Heart Fail* 2006; 8: 851–855.

19. Antunes-Correia LM, Ueno-Pardi LM, Trevisian PF, et al. The influence of aetiology on the benefits of exercise training in patients with heart failure. *Eur J Prev Cardiol* 2017; 24: 365–372.

20. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. *Circulation* 1998; 98: 2709–2715.

21. Negrao CE, Middlekauff HR, Gomes-Santos IL, et al. Effects of exercise training on neurovascular control and skeletal myopathy in systolic heart failure. *Am J Physiol Heart Circ Physiol* 2015; 308: H792–H802.

22. Chan E, Giallauria F, Vigorito C, et al. Exercise training in heart failure patients with preserved ejection fraction: a systematic review and meta-analysis. *Monaldi Arch Chest Dis* 2016; 86: 759.

23. Dieberg G, Ismail H, Giallauria F, et al. Clinical outcomes and cardiovascular responses to exercise training in heart failure patients with preserved ejection fraction: a systematic review and meta-analysis. *J Appl Physiol* 2015; 119: 726–733.

24. Pearson MJ, Mungovan SF and Smart NA. Effect of exercise on diastolic function in heart failure patients: a systematic review and meta-analysis. *Heart Fail Rev* 2017; 22: 229–242.

25. Andrade DC, Arce-Alvarez A, Toledo C, et al. Exercise training improves cardiac autonomic control, cardiac function, and arrhythmogenesis in rats with preserved-ejection fraction heart failure. *J Appl Physiol* 2017; 123: 567–577.

26. Erbs S, Höllriegel R, Linke A, et al. Exercise training in patients with advanced chronic heart failure (NYHA IIIb) promotes restoration of peripheral vasomotor function, induction of endogenous regeneration, and improvement of left ventricular function. *Circ Heart Fail* 2010; 3: 486–494.

27. Fu TC, Yang NI, Wang CH, et al. Aerobic interval training elicits different hemodynamic adaptations between heart failure patients with preserved and reduced ejection fraction. *Am J Phys Med Rehabil* 2016; 95: 15–27.

28. Alves AJ, Ribeiro F, Goldhammer E, et al. Exercise training improves diastolic function in heart failure patients. *Med Sci Sports Exerc* 2012; 44: 776–785.

29. Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. *J Am Coll Cardiol* 2013; 62: 584–592.

30. Edelmann F, Gelbrich G, Düngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study. *J Am Coll Cardiol* 2011; 58: 1780–1791.

31. Smart NA, Haluska B, Jeffriess L, et al. Exercise training in heart failure with preserved systolic function: a randomized controlled trial of the effects on cardiac function and functional capacity. *Congest Heart Fail* 2012; 18: 295–301.

32. Coelho-Filho OR, Shah RV, Mitchell R, et al. Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling. *Circulation* 2013; 128: 1225–1233.

33. Zhuang B, Sirajuddin A, Wang S, et al. Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis. *Heart Fail Rev* 2018; 23: 723–731.

34. Rommel KP, Lücke C and Lurz P. Diagnostic and prognostic value of CMR T.C. (Engl Ed) *2017; 70: 848–855.

35. Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. *JACC Cardiovasc Imaging* 2016; 9: 14–23.

36. Coelho-Filho OR, Shah RV, Neilan TG, et al. Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. *Am Heart J* 2014; 3: e000790.

37. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. *Eur Heart J* 2016; 37: 2129–2200.

38. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task
39. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *J Am Coll Cardiol* 2002; 40: 1531–1540.

40. Osman NF, Kerwin WS, McVeigh ER, et al. Cardiac motion tracking using CINE harmonic phase (HARP) magnetic resonance imaging. *Magn Reson Med* 1999; 42: 1048–1060.

41. Look D and Locker D. Time saving in measurement of NMR and EPR relaxation times. *Rev Sci Instrum* 1970; 41: 250–251.

42. Brix G, Schad LR, Deimling M, et al. Fast and precise T1 imaging using a TOMROP sequence. *Magn Res Imag* 1990; 8: 351–356.

43. Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. *Circ Cardiovas Imaging* 2013; 6: 415–422.

44. Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. *JACC Cardiovasc Imaging* 2013; 6: 672–683.

45. Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. *Am J Cardiol*. Epub ahead of print 8 December 2012. DOI: 10.1016/j.amjcard.2012.11.022.

46. Coelho-Filho OR, Mongeon FP, Mitchell R, et al. The role of transcytomedial water exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. *Circ Cardiovas Imaging*. Epub ahead of print 15 November 2012. DOI: 10.1161/ CIRCIMAGING.

47. Lewis GD, Murphy RM, Shah RV, et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. *Circ Heart Fail* 2011; 4: 276–285.

48. Lewis GD and Semigran MJ. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. *Curr Heart Fail Rep* 2004; 1: 183–189.

49. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. *Circulation* 2007; 116: 1555–1562.

50. Lewis GD, Shah RV, Pappagianopolas PP, et al. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. *Curr Heart Fail Rep* 2008; 1: 227–233.

51. Murphy RM, Shah RV, Malhotra R, et al. Exercise oscillatory ventilation in systolic heart failure: an indicator of impaired hemodynamic response to exercise. *Circulation* 2011; 124: 1442–1451.

52. Lang RM, Badano LP, Mor-avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015; 28: 1–39.

53. Naghsh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016; 29: 277–314.

54. Paim LR, Schreiber R, de Rossi G, et al. Circulating microRNAs, vascular risk, and physical activity in spinal cord-injured subjects. *J Neurotrauma* 2019; 36: 845–852.

55. Watson CJ, Gupta SK, O’Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. *Eur J Heart Fail* 2015; 17: 405–415.

56. Wong LL, Zou R, Zhou L, et al. Combining circulating microRNA and NT-proBNP to detect and categorize heart failure subtypes. *J Am Coll Cardiol* 2019; 73: 1300–1313.

57. Antunes-Correa LM, Nobre TS, Groehs RV, et al. Molecular basis for the improvement in muscle metaboreflex and mechanoreflex control in exercise-trained humans with chronic heart failure. *Am J Physiol Heart Circ Physiol* 2014; 307: H1655–H1666.

58. Liu S, Han J, Nacif MS, et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. *J Cardiovasc Magn Reson* 2012; 14: 90.

59. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of
heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013; 62: e147–e239.

60. Myers J, Brawner CA, Haykowsky MJ, *et al.* Prognosis: does exercise training reduce adverse events in heart failure? *Heart Fail Clin* 2015; 11: 59–72.

61. Hegde SM, Claggett B, Shah AM, *et al.* Physical activity and prognosis in the TOPCAT trial (treatment of preserved cardiac function heart failure with an aldosterone antagonist). *Circulation* 2017; 136: 982–992.

62. Rolim NP, Medeiros A, Rosa KT, *et al.* Exercise training improves the net balance of cardiac Ca\(^{2+}\) handling protein expression in heart failure. *Physiol Genomics* 2007; 29: 246–252.

63. McGregor G, Gaze D, Oxborough D, *et al.* Reverse left ventricular remodeling: effect of cardiac rehabilitation exercise training in myocardial infarction patients with preserved ejection fraction. *Eur J Phys Rehabil Med* 2016; 52: 370–378.

64. Ehsani AA, Biello DR, Schultz J, *et al.* Improvement of left ventricular contractile function by exercise training in patients with coronary artery disease. *Circulation* 1986; 74: 350–358.

65. McGregor G, Stohr ElJ, Oxborough D, *et al.* Effect of exercise training on left ventricular mechanics after acute myocardial infarction: an exploratory study. *Ann Rehabil Med* 2018; 61: 119–124.

66. Wisloff U, Stoylen A, Loennechen JP, *et al.* Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. *Circulation* 2007; 115: 3086–3094.

67. Giannuzzi P, Temporelli PL, Corra U, *et al.* Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the exercise in left ventricular dysfunction and chronic heart failure (ELVD-CHF) trial. *Circulation* 2003; 108: 554–559.

68. Nishi I, Noguchi T, Iwanaga Y, *et al.* Effects of exercise training in patients with chronic heart failure and advanced left ventricular systolic dysfunction receiving beta-blockers. *Circ J* 2011; 75: 1649–1655.

69. Tucker WJ, Lijauco CC, Hearon CM, *et al.* Mechanisms of the improvement in peak VO\(_2\) with exercise training in heart failure with reduced or preserved ejection fraction. *Heart Lung Circ* 2018; 27: 9–21.

70. Iles L, Pfluger H, Phrommintikul A, *et al.* Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. *J Am Coll Cardiol* 2008; 52: 1574–1580.

71. Broberg CS, Chugh SS, Conklin C, *et al.* Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. *Circ Cardiovasc Imaging* 2010; 3: 727–734.

72. Flett AS, Hayward MP, Ashworth MT, *et al.* Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. *Circulation* 2010; 122: 138–144.